Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia

Myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML) are characterized by mutations in genes encoding epigenetic modifiers and aberrant DNA methylation. DNA methyltransferase inhibitors (DMTis) are used to treat these disorders, but response is highly variable, with few means to pred...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Meldi, Kristen, Qin, Tingting, Buchi, Francesca, Droin, Nathalie, Sotzen, Jason, Micol, Jean-Baptiste, Selimoglu-Buet, Dorothée, Masala, Erico, Allione, Bernardino, Gioia, Daniela, Poloni, Antonella, Lunghi, Monia, Solary, Eric, Abdel-Wahab, Omar, Santini, Valeria, Figueroa, Maria E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4611703/
https://ncbi.nlm.nih.gov/pubmed/25822018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI78752
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados